Edwards Lifesciences Corporation
EW · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | $290,300 | $331,500 | $356,400 | $385,600 |
| Dep. & Amort. | $39,200 | $38,100 | $36,600 | $42,600 |
| Deferred Tax | -$18,000 | -$20,900 | -$24,300 | -$98,500 |
| Stock-Based Comp. | $41,200 | $37,500 | $40,200 | $50,800 |
| Change in WC | $83,500 | -$141,700 | -$150,700 | -$463,100 |
| Other Non-Cash | $137,500 | $45,700 | $22,000 | -$44,900 |
| Operating Cash Flow | $573,700 | $290,200 | $280,400 | -$127,500 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$57,500 | -$49,300 | -$56,000 | -$54,400 |
| Net Acquisitions | $0 | $3,000 | -$3,000 | -$298,200 |
| Inv. Purchases | -$1,030,800 | -$630,300 | -$647,300 | -$390,700 |
| Inv. Sales/Matur. | $669,700 | $594,100 | $845,600 | $268,100 |
| Other Inv. Act. | -$9,200 | -$89,600 | -$54,000 | -$101,500 |
| Investing Cash Flow | -$427,800 | -$172,100 | $85,300 | -$576,700 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | $0 | $0 | $0 |
| Stock Issued | $0 | $57,200 | $49,900 | $0 |
| Stock Repurch. | $157,000 | -$5,500 | -$258,600 | -$100 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | -$897,100 | $1,000 | -$50,000 | $100 |
| Financing Cash Flow | -$740,100 | $52,700 | -$258,000 | $28,600 |
| Forex Effect | -$1,000 | -$29,600 | -$17,700 | $51,000 |
| Net Chg. in Cash | -$595,200 | $141,200 | $90,000 | -$624,600 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $3,290,000 | $3,148,800 | $3,058,800 | $3,683,400 |
| End Cash | $2,694,800 | $3,290,000 | $3,148,800 | $3,058,800 |
| Free Cash Flow | $516,200 | $240,900 | $224,400 | -$177,300 |